<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3199">
  <stage>Registered</stage>
  <submitdate>13/06/2011</submitdate>
  <approvaldate>13/06/2011</approvaldate>
  <nctid>NCT01375127</nctid>
  <trial_identification>
    <studytitle>Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients</studytitle>
    <scientifictitle>An Observational Study To Collect Follow-up Clinical Data From Kidney Transplant Recipients Who Received Tofacitinib (CP-690,550) In Completed Phase 2 Studies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A3921053</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Transplantation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tofacitinib
Treatment: drugs - Tofacitinib

Subjects from Study A3921009 - 

Subjects from Study A3921030 - 


Treatment: drugs: Tofacitinib
Subjects who previously took 15 mg BID or 30 mg BID

Treatment: drugs: Tofacitinib
Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD) - All lymphoproliferative disorders diagnosed locally as PTLD based on histopathology were reported.</outcome>
      <timepoint>Baseline through Month 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Participants With Central Nervous System (CNS) Infection - Participants with CNS infection involving the brain or spinal cord, within 12 months after the last dose of tofacitinib were reported.</outcome>
      <timepoint>Baseline through Month 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Participants With Graft Failure - Graft failure which occurred within 12 months after the last dose of tofacitinib was reported. Graft failure was defined as graft nephrectomy, re-transplantation, or return to dialysis for greater than or equal to (&gt;=) 6 consecutive weeks.</outcome>
      <timepoint>Baseline through Month 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Participants Who Died</outcome>
      <timepoint>Baseline through Month 12</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects have discontinued tofacitinib prior to the planned treatment duration in 2
             completed Phase 2 studies; or have not enrolled in long-term extension studies.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  No other subjects are eligible for this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>83</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Pfizer Investigational Site - Camperdown</hospital>
    <hospital>Pfizer Investigational Site - Westmead</hospital>
    <hospital>Pfizer Investigational Site - Adelaide</hospital>
    <hospital>Pfizer Investigational Site - Clayton</hospital>
    <hospital>Pfizer Investigational Site - Parkville</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Anderlecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 4 - Krc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 15</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an observational study designed to collect follow-up clinical date on subjects who
      were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued
      treatment prematurely or did not elect to enroll in long-term extension studies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01375127</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>